Art. 39 Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…

In forcesince 28 Jan 2019cited 11×
1.

Without prejudice to paragraphs 4 and 5, a marketing authorisation shall be valid for five years.

2.

The marketing authorisation may be renewed after five years on the basis of a re-evaluation by the Agency of the risk-benefit balance.

To this end, the marketing authorisation holder shall submit a consolidated list of all documents submitted in respect of quality, safety and efficacy, including all variations introduced since the marketing authorisation was granted, at least six months before the marketing authorisation ceases to be valid in accordance with paragraph 1. The Agency may require the applicant to submit the listed documents at any time.

3.

Once renewed, the marketing authorisation shall be valid for an unlimited period, unless the Commission decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal in accordance with paragraph 2.

4.

Any authorisation which is not followed by the actual placing of the medicinal product for veterinary use on the Union market within three years after authorisation shall cease to be valid.

5.

When an authorised medicinal product previously placed on the market is no longer actually present on the market for three consecutive years, the authorisation shall cease to be valid.

6.

In exceptional circumstances and on public and/or animal health grounds the Commission may grant exemptions from the provisions of paragraphs 4 and 5. Such exemptions must be duly justified.

7.

In exceptional circumstances and following consultation with the applicant, authorisation may be granted subject to a requirement for the applicant to introduce specific procedures, in particular concerning product safety, notification to the relevant authorities of any incident relating to its use, and action to be taken. This authorisation may be granted only for objective, verifiable reasons. Continuation of the authorisation shall be linked to the annual reassessment of these conditions.

8.

When an application is submitted for a marketing authorisation in respect of veterinary medicinal products of major interest, particularly from the point of view of animal health and from the viewpoint of therapeutic innovation, the applicant may request an accelerated assessment procedure. The request shall be duly substantiated.

If the Committee for Medicinal Products for Veterinary Use accepts the request, the time-limit laid down in Article 31(3), first subparagraph, shall be reduced to 150 days.

9.

When adopting its opinion, the said Committee shall include a proposal concerning the conditions for the prescription or use of the veterinary medicinal products.

10.

Veterinary medicinal products which have been authorised in accordance with the provisions of this Regulation shall benefit from the provisions on protection in Articles 13 and 13a of Directive 2001/82/EC.

The 10 that are cited most themselves, of 11.

  • Commission Regulation (EC) No 658/2007 of 14 June 2007 concerning financial penalties fo…1Law

    … 726/2004, или за въвеждане на конкретни процедури, както е посочено в член 39, параграф 7 от Регламент (ЕО) № 726/2004; 10. задължението за …

  • Ordonnance du président du Tribunal du 20 juillet 2016. MSD Animal Health Innovation GmbH et Intervet international BV contre Agence européeDecision

    … tests submitted by a pharmaceutical company that has received an MA for a veterinary medicinal product benefit, under Article 39(10) of Regulation No 726/2004 and Articles 13 and 13a of Directive 2001/82, from a data exclusivity period of …

    20 Jul 2016 · 62015TO0729

  • Order of the Vice-President of the Court of 1 March 2017. European Medicines Agency (EMA) v MSD Animal Health Innovation GmbH and Intervet iDecision

    First, whilst, in particular, Article 36, Article 38(3) and Article 57 of Regulation No 726/2004 provide for the publication by the EMA of those three documents, those provisions specify that all information of a commercially confidential …

    1 Mar 2017 · 62016CO0512

  • Judgment of the General Court (Second Chamber) of 5 February 2018. PTC Therapeutics International Ltd v European Medicines Agency.Decision

    … αφενός, δικαιούνται την περίοδο προστασίας που προβλέπει το άρθρο 39, παράγραφος 10, του κανονισμού 726/2004. Αφετέρου, δικαιούνται, …

    5 Feb 2018 · 62015TJ0718

  • Judgment of the General Court (Second Chamber) of 5 February 2018. MSD Animal Health Innovation GmbH and Intervet international BV v EuropeaDecision

    However, those arguments cannot succeed. First, as the EMA correctly observes, MA holders – who, to obtain MAs, have submitted safety study data – enjoy protection of their data in various respects after the MA procedure has been …

    5 Feb 2018 · 62015TJ0729

  • Commission Regulation (EU) No 488/2012 of 8 June 2012 amending Regulation (EC) No 658/20…1Law

    … 726/2004, или за въвеждане на конкретни процедури, както е посочено в член 39, параграф 7 от Регламент (ЕО) № 726/2004; 10. задължението за …

  • Commission Regulation (EU) No 488/2012 of 8 June 2012 amending Regulation (EC) No 658/20…1Law

    … to in Article 14(7) and (8) of Regulation (EC) No 726/2004 or to introduce the specific procedures referred to in Article 39(7) of Regulation (EC) No 726/2004; the obligation to notify the Agency of the dates of actual marketing and of the …

  • Regulation (EU) 2019/5Lawamends

  • Opinion of Advocate General Bobek delivered on 21 December 2016.Decision

    Nach Art. 89 der Verordnung Nr. 726/2004 „[gelten die] in Artikel 14 Absatz 11 und Artikel 39 Absatz 10 genannten Schutzzeiträume … nicht für Referenzarzneimittel, deren Genehmigung vor dem [20. November 2005] beantragt wurde“.

    21 Dec 2016 · 62015CC0629

  • Opinion of Advocate General Hogan delivered on 11 September 2019. MSD Animal Health Innovation GmbH and Intervet International BV v EuropeanDecision

    It also expressed doubts as to whether non-clinical and clinical studies were in themselves confidential as they may be limited to satisfying a regulatory scheme prescribed by the EMA and contain no new material. [Ibid., paragraph 44.] The …

    11 Sep 2019 · 62018CC0178